NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer patients: drug combo targets tough tumors
Disease control Not yet recruitingThis study tests a new combination of two drugs (becotatug vedotin and pucotenlimab), with or without radiation, as a first treatment for people with advanced non-small cell lung cancer that has a specific protein (EGFR) on its surface. About 39 participants will receive the drug…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for lung cancer: experimental drug combo enters trial
Disease control Not yet recruitingThis study tests a new drug called SCTB41 combined with the chemotherapy docetaxel in 90 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination is safe and works better than docetaxel alone. Participants will…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy targets tough lung cancers
Disease control Not yet recruitingThis study tests a new drug called ALK202 combined with other medicines for people with advanced non-small cell lung cancer. The trial will include 252 participants and aims to see if the combinations are safe and can shrink tumors. It is divided into two phases: first to find th…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for Hard-to-Treat lung cancer: drug combo targets bulky tumors
Disease control Not yet recruitingThis study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with a large, advanced type of lung cancer (stage III NSCLC) live longer without the cancer growing. About 204 adults aged 18-75 with tumors at least 5 cm wide or lymph nodes at least …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Donor cells join fight against advanced cancers
Disease control Not yet recruitingThis early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for KRAS G12D lung cancer: targeted drug combo enters trial
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called GFH375, alone or combined with other drugs (cetuximab or pemetrexed), as a first treatment for advanced non-small cell lung cancer with a specific KRAS G12D mutation. The study will enroll 90 people who have not had prior treatment. The …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for lung cancer patients: drug combo targets treatment resistance
Disease control Not yet recruitingThis study tests a new combination of two drugs—gemcitabine (chemotherapy) and ivonescimab (a targeted therapy)—in people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if this combination can shrink tumors or sto…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Lung cancer trial aims to boost tumor shrinkage while protecting lungs
Disease control Not yet recruitingThis phase 2 trial tests a new approach for advanced non-small cell lung cancer. It combines chemotherapy and immunotherapy with a special 'high-low mixed-dose' radiotherapy that gives a strong dose to large tumors and a lower dose to smaller ones. The goal is to shrink tumors fa…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Radiation boosts immunotherapy in lung cancer? new trial aims to find out
Disease control Not yet recruitingThis study looks at people with stage III non-small cell lung cancer who had chemotherapy plus immunotherapy before surgery, and still had cancer in their lymph nodes after the tumor was removed. Half will get standard immunotherapy alone after surgery, and the other half will ge…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to tackle lung cancer brain metastases
Disease control Not yet recruitingThis study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment.…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New strategy aims to tame treatment side effects in lung cancer patients
Symptom relief Not yet recruitingThis study tests a special care plan to help Chinese patients with advanced EGFR-mutated lung cancer who are taking the drug amivantamab. The plan focuses on preventing common side effects like blood clots, skin rashes, and infusion reactions. About 122 adults will join to see if…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE4 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Lung cancer drug anlotinib tested in Real-World review after treatment failure
Knowledge-focused Not yet recruitingThis study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Henan Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Lung cancer immune markers under the microscope
Knowledge-focused Not yet recruitingThis observational study aims to understand how the immune system and tumor markers relate to treatment response in 500 people with advanced non-small cell lung cancer. Participants will provide tumor samples before and during immunochemotherapy. The study does not test any new d…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:25 UTC